Literature DB >> 22051774

Chronic inflammatory cardiomyopathy of interferon γ-overexpressing transgenic mice is mediated by tumor necrosis factor-α.

Michael Torzewski1, Philip Wenzel, Hartmut Kleinert, Christoph Becker, Jasmin El-Masri, Elena Wiese, Moritz Brandt, Andrea Pautz, Laura Twardowski, Edgar Schmitt, Thomas Münzel, Kurt Reifenberg.   

Abstract

We recently described a model of inflammatory cardiomyopathy in interferon (IFN)-γ overexpressing transgenic mice stably circulating IFN-γ in the serum referred to as SAP--IFN-γ mice. SAP-IFN-γ transgenic mice show cardiac infiltration by mononuclear leukocytes, culminating in dilated cardiomyopathy characterized by an increase of left ventricular end diastolic diameter and reduction of fractional shortening. We hypothesized that the pathological mechanism underlying SAP-IFN-γ cardiomyopathy might be mediated by (auto)immune processes or tumor necrosis factor (TNF)-α synthesis from IFN-γ-activated macrophages. To verify these hypotheses, we crossed SAP-IFN-γ transgenic mice with immunodeficient Rag1(-/-) or TNF-α(-/-) knockout mice and analyzed the cardiac phenotype of the resulting double-mutant offspring. Immunodeficient Rag1(-/-) SAP-IFN-γ mice had a decreased impaired life span and intensive cardiac inflammatory reactions, showing that the cardiotoxic IFN-γ effect operative in SAP-IFN-γ mice was not mediated by an adaptive immune mechanism. SAP-IFN-γ TNF-α(-/-) hearts showed virtually no histopathological alterations, a significant reduction of cardiac infiltration by CD11c(+) dendritic cells and F4/80(+) macrophages, almost complete normalization of cardiac troponin T levels in serum and of left ventricular end diastolic diameter and fractional shortening, and a dramatic increase of life span, compared with SAP-IFN-γ transgenic controls. Thus, myocarditis and cardiomyopathy developing in IFN-γ-overexpressing transgenic mice is, to a significant degree, mediated by TNF-α. TNF-α-mediated cardiotoxicity in SAP-IFN-γ transgenic mice is independent of changes of apoptosis.
Copyright © 2012 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22051774     DOI: 10.1016/j.ajpath.2011.09.006

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  10 in total

1.  Interferon-γ causes cardiac myocyte atrophy via selective degradation of myosin heavy chain in a model of chronic myocarditis.

Authors:  Pippa F Cosper; Pamela A Harvey; Leslie A Leinwand
Journal:  Am J Pathol       Date:  2012-10-08       Impact factor: 4.307

Review 2.  Origin of cardiomyocytes in the adult heart.

Authors:  Annarosa Leri; Marcello Rota; Francesco S Pasqualini; Polina Goichberg; Piero Anversa
Journal:  Circ Res       Date:  2015-01-02       Impact factor: 17.367

3.  Proinflammatory effects of interferon gamma in mouse adenovirus 1 myocarditis.

Authors:  Mary K McCarthy; Megan C Procario; Nele Twisselmann; J Erby Wilkinson; Ashley J Archambeau; Daniel E Michele; Sharlene M Day; Jason B Weinberg
Journal:  J Virol       Date:  2014-10-15       Impact factor: 5.103

Review 4.  Human heart failure: is cell therapy a valid option?

Authors:  Marcello Rota; Annarosa Leri; Piero Anversa
Journal:  Biochem Pharmacol       Date:  2013-11-13       Impact factor: 5.858

5.  Myocardial gene expression of T-bet, GATA-3, Ror-γt, FoxP3, and hallmark cytokines in chronic Chagas disease cardiomyopathy: an essentially unopposed TH1-type response.

Authors:  Luciana Gabriel Nogueira; Ronaldo Honorato Barros Santos; Alfredo Inácio Fiorelli; Eliane Conti Mairena; Luiz Alberto Benvenuti; Edimar Alcides Bocchi; Noedir Antonio Stolf; Jorge Kalil; Edecio Cunha-Neto
Journal:  Mediators Inflamm       Date:  2014-07-24       Impact factor: 4.711

6.  Disease Tolerance and Pathogen Resistance Genes May Underlie Trypanosoma cruzi Persistence and Differential Progression to Chagas Disease Cardiomyopathy.

Authors:  Christophe Chevillard; João Paulo Silva Nunes; Amanda Farage Frade; Rafael Ribeiro Almeida; Ramendra Pati Pandey; Marilda Savóia Nascimento; Jorge Kalil; Edecio Cunha-Neto
Journal:  Front Immunol       Date:  2018-12-03       Impact factor: 7.561

7.  miRNAs may play a major role in the control of gene expression in key pathobiological processes in Chagas disease cardiomyopathy.

Authors:  Laurie Laugier; Ludmila Rodrigues Pinto Ferreira; Frederico Moraes Ferreira; Sandrine Cabantous; Amanda Farage Frade; Joao Paulo Nunes; Rafael Almeida Ribeiro; Pauline Brochet; Priscila Camillo Teixeira; Ronaldo Honorato Barros Santos; Edimar A Bocchi; Fernando Bacal; Darlan da Silva Cândido; Vanessa Escolano Maso; Helder I Nakaya; Jorge Kalil; Edecio Cunha-Neto; Christophe Chevillard
Journal:  PLoS Negl Trop Dis       Date:  2020-12-22

8.  Suppression of Inflammatory Cardiac Cytokine Network in Rats with Untreated Obesity and Pre-Diabetes by AT2 Receptor Agonist NP-6A4.

Authors:  Madhavi P Gavini; Abuzar Mahmood; Anthony M Belenchia; Paige Beauparlant; Senthil A Kumar; Sivakumar Ardhanari; Vincent G DeMarco; Lakshmi Pulakat
Journal:  Front Pharmacol       Date:  2021-06-18       Impact factor: 5.810

9.  P2×7 purinergic signaling in dilated cardiomyopathy induced by auto-immunity against muscarinic M2 receptors: autoantibody levels, heart functionality and cytokine expression.

Authors:  Camila Guerra Martinez; Daniel Zamith-Miranda; Marcia Gracindo da Silva; Karla Consort Ribeiro; Izaíra Trincani Brandão; Celio Lopes Silva; Bruno Lourenço Diaz; Maria Bellio; Pedro Muanis Persechini; Eleonora Kurtenbach
Journal:  Sci Rep       Date:  2015-11-23       Impact factor: 4.379

10.  Histiocyte predominant myocarditis resulting from the addition of interferon gamma to cyclophosphamide-based lymphodepletion for adoptive cellular therapy.

Authors:  Brett A Schroeder; Ralph Graeme Black; Sydney Spadinger; Shihong Zhang; Karan Kohli; Jianhong Cao; Jose G Mantilla; Ernest U Conrad; Stanley R Riddell; Robin L Jones; Cassian Yee; Seth M Pollack
Journal:  J Immunother Cancer       Date:  2020-04       Impact factor: 13.751

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.